Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by JLGeminion Apr 01, 2011 1:06pm
210 Views
Post# 18373876

Investment Strategy - Buy, Hold, Overweight

Investment Strategy - Buy, Hold, Overweight

What is your investment strategy for investing in Oncolytics?  Institutional investors are buying.  They are buying holdings held by retail investors.  To encourage retail investors to sell, they will manage the price down until the last possible moment.  It happened to Dendreon in 2009 as demonstrated below.  The market is about making money and taking advantage of situation.  Trust your judgement.

 

My advice is to hold onto your shares, buy, overweight your position, and use margin.  The choice is yours.  The opportunity for the easy money to be made on Oncolytics is now.  My strategy is simple.  The more shares that I own: the more money that I make.  

 

Trading of Dendreon on the NASDAQ

 

Date

Close

Volume

 

 

 

31-Dec-08

4.58

714,221

15-Jan-09

4.61

2,471,820

30-Jan-09

3.37

1,317,839

17-Feb-09

3.65

1,606,247

27-Feb-09

3.05

2,757,763

16-Mar-09

3.95

4,921,467

31-Mar-09

4.20

2,296,321

01-Apr-09

4.14

3,199,650

02-Apr-09

4.34

2,427,867

03-Apr-09

5.99

22,497,200

06-Apr-09

6.58

19,585,750

07-Apr-09

6.58

7,346,062

08-Apr-09

6.37

5,392,639

09-Apr-09

6.30

4,234,697

13-Apr-09

7.30

12,775,310

14-Apr-09

16.99

65,120,890

15-Apr-09

17.17

19,294,060

16-Apr-09

17.03

6,894,881

17-Apr-09

17.99

17,799,470

20-Apr-09

19.52

17,724,250

21-Apr-09

19.74

11,008,510

22-Apr-09

20.12

7,358,435

23-Apr-09

20.33

6,123,418

24-Apr-09

20.08

7,393,327

27-Apr-09

21.55

18,569,850

28-Apr-09

11.81

28,070,740

29-Apr-09

22.94

48,235,790

30-Apr-09

21.20

17,468,950

Yesterday

 

 

31-Mar-11

37.43

11,019,920

 

Bullboard Posts